Xintela’s year-end report did not reveal any substantial surprises. The recent rights issue and loan facility have given the company temporary financial relief. In February, Xintela announced its clinical study with XSTEM in difficult-to-heal leg ulcers (VLU) was completed, and the final study results are expected by the end of May. In the report, CEO Evy Lundgren-Åkerlund referred to discussions regarding investigator-initiated phase II studies with XSTEM in both VLU and osteoarthritis. If these studies materialise, they could change Xintela’s capital needs and would prompt us to revise our model. As of now, we make only minor adjustments and thus keep the fair value at 1.04 SEK per share.
Read the full report here.